Aberrant methylation of Secreted Apoptosis-Related Protein 2 (SARP2) in pure pancreatic juice in the diagnosis of pancreatic neoplasms

Pancreas

Volumn 32, Issue 4, 2006, Pages 382-389

  Watanabe, Hiroyuki ^a   Okada, Gensaku ^a   Ohtsubo, Koushiro ^a   Yao, Fan ^a   Jiang, Pei Hong ^a   Mouri, Hisatsugu ^a   Wakabayashi, Tokio ^b   Sawabu, Norio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

Aberrant methylation of SARP2; Chronic pancreatitis; Intraductal papillary mucinous neoplasm of the pancreas (IPMN); Pancreatic carcinoma; Pure pancreatic juice

Indexed keywords

DNA; PROTEIN; SECRETED APOPTOSIS RELATED PROTEIN 2; UNCLASSIFIED DRUG; MEMBRANE PROTEIN; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CHRONIC PANCREATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MALE; NUCLEOTIDE SEQUENCE; PANCREAS CARCINOMA; PANCREAS JUICE; PANCREAS TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR DIAGNOSIS; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROMOTER REGION; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PANCREATIC JUICE; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS);

EID: 33646839964     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpa.0000221617.89376.38     Document Type: Article

References (27)

1. Kameya S, Kuno N, Kasugai T. The diagnosis of pancreatic cancer by pancreatic juice cytology. Acta Cytol. 1981;25:354-360.
2. Nakaizumi A, Tatsuta M, Uehara H, et al. Cytologic examination of pure pancreatic juice in the diagnosis of pancreatic carcinoma. Cancer. 1992;70:2610-2614.
3. Watanabe H, Sawabu N, Ohta H, et al. Identification of K-ras oncogene mutations in the pure pancreatic juice of patients with ductal pancreatic cancers. Jpn J Cancer Res. 1993;84:961-965.
4. Watanabe H, Sawabu N, Songür Y, et al. Detection of K-ras point mutations at codon 12 in pure pancreatic juice for the diagnosis of pancreatic cancer by PCR-RFLP analysis. Pancreas. 1996;12:18-24.
5. Watanabe H, Miyagi C, Yamaguchi Y, et al. Detection of K-ras point mutations at codon 12 in pancreatic juice for the diagnosis of pancreatic cancer by hybridization protection assay: a simple method for the determination of the types of point mutations. Jpn J Cancer Res. 1996;87:466-474.
6. Watanabe H, Yamaguchi Y, Ha A, et al. Quantitative determination of K-ras mutations in pancreatic juice for diagnosis of pancreatic cancer using hybridization protection assay. Pancreas. 1998;17:341-347.
7. Yamaguchi Y, Watanabe H, Songur Y, et al. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its clinical application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res. 1999;5:1147-1153.
8. Ha A, Watanabe H, Yamaguchi Y, et al. Usefulness of supernatant of pancreatic juice for genetic analysis of K-ras in diagnosis of pancreatic carcinoma. Pancreas. 2001;23:356-363.
9. Wang Y, Yamaguchi Y, Watanabe H, et al. Detection of p53 gene mutations in the supernatant of pancreatic juice and plasma from the patients with pancreatic carcinoma. Pancreas. 2004;28:13-19.
10. Yanagisawa A, Ohtake K, Ohhashi K, et al. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res. 1993;53:953-956.
11. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res. 1994;54:3568-3573.
12. Tada M, Teratani T, Komatsu Y, et al. Quantitative analysis of ras gene mutation in pancreatic juice for the diagnosis of pancreatic adenocarcinoma. Dig Dis Sci. 1998;43:15-20.
13. Ryu B, Jones J, Blages NJ, et al. Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. Cancer Res. 2002;62:819-826.
14. Watanabe H, Okada G, Ohtsubo K, et al. Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis. Pancreas. 2005;30:349-354.
15. Sato N, Fukushima N, Maitra A, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003;63:3735-3742.
16. Melkonyan HS, Chang WC, Shapiro JP, et al. SARPs: a family of secreted apoptosis-related proteins. Proc Natl Acad Sci U S A. 1997;94:13636-13641.
17. Clinical, surgical, and comprehensive findings. In: Hermanek P, Sobin LH, eds. TNM Classification of Malignant Tumours. Fully revised 4th ed. Springer-Verlag; 1987.
18. Clinical, surgical, and comprehensive findings. In: Japan Pancreas Society, ed. Classification of Pancreatic Carcinoma. 1st English ed. Kanehara Co., Tokyo; 1996:2-14.
19. Colcia E, Capella C, Kloppel G. Tumors of the pancreas. Atlas of Tumor Pathology, 3rd series Fascicle 20. Washington, DC: Armed Forces Institute of Pathology; 1997.
20. Homma T, Harada H, Koizumi M. Diagnostic criteria for chronic pancreatitis by the Japan Pancreas Society. Pancreas. 1997;15:14-15.
21. Bowtell DDL. Rapid isolation of eukaryotic DNA. Anal Biochem. 1987;162:463-465.
22. Jéanpièrre M. A rapid method for the purification of DNA from blood. Nucleic Acids Res. 1987;15:9611.
23. Herman JG, Grff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
24. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for gene upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet. 2002;31:141-149.
25. Zou H, Molina JR, Harrington JJ, et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer. 2005;116:584-591.
26. Suzuki H, Watkins DN, Jair KW, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 2004;36:417-422.
27. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. 2004;363: 1283-1285.